Study identifier:ACE-LY-004
ClinicalTrials.gov identifier:NCT02213926
EudraCT identifier:2014-002117-28
CTIS identifier:2023-509352-34-00
An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Phase 2
No
ACP-196 (acalabrutinib)
All
124
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2024 by AcertaPharma
AcertaPharma
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: ACP-196 (acalabrutinib) Regimen 1 ACP-196 (acalabrutinib) Regimen 1 | - |